LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regeneron Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

492.82 2.13

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

491.18

Максимум

499.69

Ключови измерители

By Trading Economics

Приходи

-109M

809M

Продажби

-761M

3B

P/E

Средно за сектора

12.47

51.198

EPS

8.22

Дивидентна доходност

0.72

Марж на печалбата

26.701

Служители

15,158

EBITDA

-54M

1B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+46.86% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.72%

2.40%

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-22B

53B

Предишно отваряне

490.69

Предишно затваряне

492.82

Настроения в новините

By Acuity

37%

63%

117 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.05.2025 г., 11:55 ч. UTC

Придобивния, сливания и поглъщания

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29.04.2025 г., 11:07 ч. UTC

Печалби

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4.02.2025 г., 12:13 ч. UTC

Печалби

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

5.06.2025 г., 01:41 ч. UTC

Придобивния, сливания и поглъщания

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30.05.2025 г., 08:58 ч. UTC

Горещи акции

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30.05.2025 г., 08:56 ч. UTC

Пазарно говорене

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19.05.2025 г., 17:52 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19.05.2025 г., 16:13 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19.05.2025 г., 14:42 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19.05.2025 г., 13:33 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19.05.2025 г., 11:10 ч. UTC

Придобивния, сливания и поглъщания

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19.05.2025 г., 11:10 ч. UTC

Придобивния, сливания и поглъщания

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19.05.2025 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19.05.2025 г., 11:08 ч. UTC

Придобивния, сливания и поглъщания

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29.04.2025 г., 18:04 ч. UTC

Пазарно говорене
Печалби

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29.04.2025 г., 14:39 ч. UTC

Пазарно говорене
Печалби

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29.04.2025 г., 14:29 ч. UTC

Печалби

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29.04.2025 г., 13:11 ч. UTC

Печалби

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29.04.2025 г., 10:32 ч. UTC

Печалби

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29.04.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 1Q Rev $3.03B >REGN

29.04.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 1Q Net $808.7M >REGN

29.04.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 1Q EPS $7.27 >REGN

29.04.2025 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22.04.2025 г., 10:51 ч. UTC

Топ новини

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4.02.2025 г., 11:58 ч. UTC

Печалби

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4.02.2025 г., 11:36 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4.02.2025 г., 11:35 ч. UTC

Печалби

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

Сравнение с други в отрасъла

Ценова промяна

Regeneron Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

46.86% нагоре

12-месечна прогноза

Среден 724.35 USD  46.86%

Висок 900 USD

Нисък 535 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Regeneron Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

23 ratings

17

Купи

5

Задържане

1

Продай

Техническа оценка

By Trading Central

542.44 / 599.76Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

117 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.